ASCO: Myovant details speedy effects of prostate cancer med relugolix

ASCO: Myovant details speedy effects of prostate cancer med relugolix

Source: 
Fierce Biotech
snippet: 

Last fall, Myovant reported phase 3 data that set its prostate cancer med up for an FDA filing, but it kept most details close to the vest. Now, it’s unveiling more as it awaits the agency’s decision.

The new data, to be presented at the virtual annual meeting of the American Society of Clinical Oncology, show just how quickly the drug, relugolix, can lower testosterone, which drives the growth of prostate cancer.